Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, today announced a strategic collaboration with Shanghai MediTrust Health Technology Group Co., Ltd. (hereinafter referred to as "MediTrust Health") in Shanghai. Both parties will leverage diversified commercial insurance payment pathways, exclusive pharmaceutical supply chain networks, and Internet service platforms to conduct comprehensive and in-depth strategic cooperation. By establishing an ‘Internet + Medical + Pharmaceutical + Insurance’ service closed-loop covering the entire drug lifecycle, this partnership aims to enhance the accessibility and affordability of innovative drugs while alleviating payment pressure on patients.

Representatives from Mabwell and MediTrust Health signed the strategic partnership agreement

The collaboration will rely on MediTrust Health’s three major infrastructures: the diversified pharmaceutical payment platform, the pharmaceutical supply chain, and the AI Intelligent Center. Combined with Mabwell’s pipeline in autoimmune, bone health, and oncology, the two companies will focus on in-depth collaboration regarding the one-stop user service platform, "One-Code Direct Payment", and intelligent medication commercialization solutions.

Mr. Han Li, Vice President of Mabwell at the MediTrust Health Commercial Insurance Smart Operations Center, to experience its one-stop user service platform, “One-Code Direct Payment"

Mr. Han Li, Vice President of Mabwell, stated, We are delighted to reach a multi-dimensional and deep strategic partnership with MediTrust Health to jointly improve the patient medical experience. Mabwell remains the patient-centered commitment and focuses on oncology and age-related diseases. We hope this cooperation will actively explore new models for innovative drug health management services and innovative commercial health insurance payments, further breaking down the barriers between high-quality medical resources and patients, so that more patients can benefit from high-quality biologics.

Mr. Hao Feng, Chief Innovation Officer of MediTrust Health, stated, This partnership marks the official commencement of a new stage of deep strategic cooperation between the two parties, starting a new chapter of resource synergy and win-win innovation. Based on Mabwell’s professional strength in R&D, coupled with MediTrust Health’s diversified payment and supply chain capabilities, we will further facilitate the implementation of innovative drug payments and services, bringing better and more accessible treatment options to patients.

About MediTrust

Meditrust Health is China's leading diversified payment platform in China's pharmaceutical sector. The company is consistently dedicated to addressing the financing and payment challenges faced by patients, insurers, and pharmaceutical companies, thereby contributing to the transformation of China’s healthcare payment system. Leveraging AI technology, the company is reshaping the healthcare payment ecosystem and has successfully achieved synergy and mutual benefits among all stakeholders in the healthcare system.